Free Trial
NASDAQ:ORMP

Oramed Pharmaceuticals (ORMP) Stock Price, News & Analysis

Oramed Pharmaceuticals logo
$2.16 +0.06 (+2.86%)
Closing price 04:00 PM Eastern
Extended Trading
$2.15 -0.01 (-0.42%)
As of 04:01 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Oramed Pharmaceuticals Stock (NASDAQ:ORMP)

Key Stats

Today's Range
$2.12
$2.19
50-Day Range
$2.10
$2.38
52-Week Range
$1.82
$3.09
Volume
47,183 shs
Average Volume
142,151 shs
Market Capitalization
$88.24 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
Hold

Company Overview

Oramed Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
11th Percentile Overall Score

ORMP MarketRank™: 

Oramed Pharmaceuticals scored higher than 11% of companies evaluated by MarketBeat, and ranked 903rd out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Earnings Growth

    Earnings for Oramed Pharmaceuticals are expected to decrease in the coming year, from ($0.03) to ($0.19) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Oramed Pharmaceuticals is -4.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Oramed Pharmaceuticals is -4.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Oramed Pharmaceuticals has a P/B Ratio of 0.60. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Oramed Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    1.35% of the float of Oramed Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Oramed Pharmaceuticals has a short interest ratio ("days to cover") of 6.5.
  • Change versus previous month

    Short interest in Oramed Pharmaceuticals has recently decreased by 2.88%, indicating that investor sentiment is improving.
  • Dividend Yield

    Oramed Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Oramed Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    1.35% of the float of Oramed Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Oramed Pharmaceuticals has a short interest ratio ("days to cover") of 6.5.
  • Change versus previous month

    Short interest in Oramed Pharmaceuticals has recently decreased by 2.88%, indicating that investor sentiment is improving.
  • News Sentiment

    Oramed Pharmaceuticals has a news sentiment score of 0.39. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.90 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for Oramed Pharmaceuticals this week, compared to 1 article on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Oramed Pharmaceuticals insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    13.70% of the stock of Oramed Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 12.73% of the stock of Oramed Pharmaceuticals is held by institutions.

  • Read more about Oramed Pharmaceuticals' insider trading history.
Receive ORMP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Oramed Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ORMP Stock News Headlines

Oramed Pharmaceuticals Inc. (ORMP) - Yahoo Finance
Banks aren’t ready for this altcoin—are you?
In crypto, timing is everything. By the time the masses catch wind of this, the biggest gains could be ancient history. Are you ready to potentially change your financial future forever?
Oramed Pharm Extends Stock Buyback Program
See More Headlines

ORMP Stock Analysis - Frequently Asked Questions

Oramed Pharmaceuticals' stock was trading at $2.42 at the beginning of 2025. Since then, ORMP shares have decreased by 10.7% and is now trading at $2.16.
View the best growth stocks for 2025 here
.

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) released its quarterly earnings data on Thursday, May, 15th. The biotechnology company reported ($0.19) EPS for the quarter, missing the consensus estimate of ($0.03) by $0.16. The biotechnology company had revenue of $2 million for the quarter.

Shares of ORMP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Oramed Pharmaceuticals investors own include TransEnterix (TRXDW), Compugen (CGEN), Sarepta Therapeutics (SRPT), NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD) and Gilead Sciences (GILD).

Company Calendar

Last Earnings
5/15/2025
Today
7/02/2025
Next Earnings (Estimated)
8/13/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED PRODUCTS
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ORMP
Employees
10
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$19.06 million
Pretax Margin
-1,225.60%

Debt

Sales & Book Value

Annual Sales
$1.34 million
Price / Cash Flow
N/A
Book Value
$3.61 per share
Price / Book
0.60

Miscellaneous

Free Float
35,254,000
Market Cap
$88.44 million
Optionable
Optionable
Beta
1.59

Social Links

Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

This page (NASDAQ:ORMP) was last updated on 7/2/2025 by MarketBeat.com Staff
From Our Partners